Dr Rishabh Jain· @DrRishabhOnco · X·· 12 小时前评分70
正文 · 原文
🚨 Ivonescimab beats durvalumab in biliary tract cancer!
Phase III HARMONi-GI1 | #ESMO26
682 patients | 1L advanced BTC
🔥 Median OS: 14.9 vs 12.1 months (HR 0.75)
🔥 Median PFS: 8.4 vs 5.8 months (HR 0.61)
A significant survival advantage over the TOPAZ-1 regimen!
Could PD-1/VEGF bispecific therapy redefine 1L BTC?
@myesmo @ESMO_open @ASCO @oncoalert
48 浏览 · 0 赞 · 0 转发 · 0 回复
🚨 #ESMO26: Durvalumab’s first-line dominance in biliary tract cancer challenged! HARMONi-GI1 | Phase III Ivonescimab + GemCis vs Durvalumab + GemCis 🔥 OS: 14.9 vs 12.1 months (HR 0.75) 📈 PFS: 8.4 vs 5.8 months (HR 0.61) 🎯 ORR: 53.8% vs 32.5% PD-1/VEGF bispecific therapy could redefine first-line BTC treatment. @my_esmo @ESMO_open @ASCO @OncoAlert在 X 查看被引用的帖子
来源：Dr Rishabh Jain · x.com